InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
1
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the full record of transactions filed by Kelly Ralph David, Director. Officer active across 5 companies, notably Invesco Real Estate Income Trust Inc.. In total, 12 filings have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €197k. Activity tracked since 21 July 2022. The latest transaction was disclosed on 1 April 2026 (J). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Kelly Ralph David
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报12 总计
2,000 股@ US$100.0046.7% 占其流量Common Limited Liability Company UnitsSEC:0001193125-26-141788:0
10,000 股@ US$20.00100.0% 占其流量Common Limited Liability Company UnitsSEC:0001193125-26-141845:0
2,683.766 股0Class E Common Stock, $0.01 par valueSEC:0001632674-25-000009:0
2,448.119 股0Class E Common Stock, $0.01 par valueSEC:0001632674-25-000004:0
7,032 股0Common StockSEC:0000950170-25-079846:0
2,180.93 股0Class E Common Stock, $0.01 par valueSEC:0001632674-24-000007:0
2,414 股0Common StockSEC:0000950170-24-067344:0
835.097 股0Common Stock, $0.01 par valueSEC:0001632674-24-000003:0
747.152 股0Common Stock, $0.01 par valueSEC:0001209191-23-055996:0
2,229 股0Common StockSEC:0000899243-23-013385:0
2,000 股@ US$100.00100.0% 占其流量Common Limited Liability Company UnitsSEC:0001825265-22-000006:0
标准退出：2022年10月6日 (T+90)
2,078 股0Common StockSEC:0000899243-22-026588:0
12 条申报中的 12 条
About Kelly Ralph David
Ralph David Kelly is the General Counsel at Akero Therapeutics, Inc. He oversees legal and regulatory matters, ensuring the company's compliance. His expertise is essential for managing legal risks.
